FDA Will Seek More Authority Over Manufacturing In Wake Of J&J Recalls
Executive Summary
FDA will monitor more closely manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
You may also be interested in...
Rapamune Off-Label Suit Prompts Congressional Investigation
House Oversight Committee is investigating allegations Wyeth promoted Rapamune for unapproved uses. Chairman Towns says he is concerned the drug was targeted to high-risk African-Americans; Pfizer says the drug is not contraindicated for this population.
Rapamune Off-Label Suit Prompts Congressional Investigation
House Oversight Committee is investigating allegations Wyeth promoted Rapamune for unapproved uses. Chairman Towns says he is concerned the drug was targeted to high-risk African-Americans; Pfizer says the drug is not contraindicated for this population.
J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
FDA could seek misdemeanor charges against J&J officers under the Park Doctrine, which can be invoked against executives who could have prevented adulteration or misbranding of a drug. California Republican Issa says regardless whether criminal indictments come, the case "could be fair warning" to other firms regarding quality system failures.